Blair William & Co. IL Has $1.69 Million Stake in Aratana Therapeutics Inc (PETX)

Blair William & Co. IL reduced its position in Aratana Therapeutics Inc (NASDAQ:PETX) by 52.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 288,525 shares of the biopharmaceutical company’s stock after selling 312,955 shares during the quarter. Blair William & Co. IL’s holdings in Aratana Therapeutics were worth $1,685,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of PETX. BlackRock Inc. lifted its position in shares of Aratana Therapeutics by 2.7% during the 3rd quarter. BlackRock Inc. now owns 3,439,584 shares of the biopharmaceutical company’s stock valued at $20,087,000 after acquiring an additional 91,344 shares during the period. Engaged Capital LLC lifted its position in shares of Aratana Therapeutics by 20.0% during the 2nd quarter. Engaged Capital LLC now owns 2,400,000 shares of the biopharmaceutical company’s stock valued at $10,200,000 after acquiring an additional 400,000 shares during the period. General American Investors Co. Inc. lifted its position in shares of Aratana Therapeutics by 15.9% during the 3rd quarter. General American Investors Co. Inc. now owns 1,874,364 shares of the biopharmaceutical company’s stock valued at $10,946,000 after acquiring an additional 256,441 shares during the period. Massachusetts Financial Services Co. MA lifted its position in shares of Aratana Therapeutics by 8.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,491,196 shares of the biopharmaceutical company’s stock valued at $8,709,000 after acquiring an additional 114,998 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in shares of Aratana Therapeutics by 22.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,118,836 shares of the biopharmaceutical company’s stock valued at $6,534,000 after acquiring an additional 208,508 shares during the period. 67.92% of the stock is currently owned by institutional investors.

A number of research firms recently issued reports on PETX. BidaskClub upgraded shares of Aratana Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, October 23rd. Zacks Investment Research downgraded shares of Aratana Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, November 8th. ValuEngine upgraded shares of Aratana Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, October 22nd. Finally, TheStreet upgraded shares of Aratana Therapeutics from a “d” rating to a “c-” rating in a report on Wednesday, November 21st. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $8.15.

PETX opened at $6.39 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.70 and a current ratio of 3.17. Aratana Therapeutics Inc has a 1-year low of $3.67 and a 1-year high of $7.16. The firm has a market cap of $309.74 million, a price-to-earnings ratio of -6.59 and a beta of 1.99.

Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.03. Aratana Therapeutics had a negative net margin of 52.94% and a negative return on equity of 15.08%. The firm had revenue of $21.56 million for the quarter, compared to the consensus estimate of $5.70 million. On average, equities research analysts anticipate that Aratana Therapeutics Inc will post -0.25 earnings per share for the current year.

In other Aratana Therapeutics news, insider Peter Steven St sold 11,513 shares of the company’s stock in a transaction on Tuesday, October 30th. The shares were sold at an average price of $5.86, for a total transaction of $67,466.18. Following the transaction, the insider now owns 562,720 shares in the company, valued at $3,297,539.20. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Ernst Heinen sold 19,308 shares of the company’s stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $6.95, for a total transaction of $134,190.60. Following the transaction, the insider now owns 135,694 shares in the company, valued at approximately $943,073.30. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 106,513 shares of company stock worth $660,966. Corporate insiders own 5.30% of the company’s stock.

WARNING: “Blair William & Co. IL Has $1.69 Million Stake in Aratana Therapeutics Inc (PETX)” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/12/07/blair-william-co-il-has-1-69-million-stake-in-aratana-therapeutics-inc-petx.html.

Aratana Therapeutics Profile

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

Featured Article: What does relative strength index mean?

Want to see what other hedge funds are holding PETX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aratana Therapeutics Inc (NASDAQ:PETX).

Institutional Ownership by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply